How PBMs Can Help Plan Sponsors Combat Fraud, Waste and Abuse

September 16, 2021

Carrie Aiken, Navitus’ Vice President of Corporate Compliance and Chief Compliance Officer, shares her perspective on how PBMs can help plan sponsors manage the risks of fraud, waste and abuse.

The U.S. health care system loses tens of billions of dollars every year to fraud, waste and abuse. In fact, the National Health Care Anti-Fraud Association estimates that health care fraud costs the nation about $68 billion annually. A large portion of these costs are attributed to pharmacy spend, including duplicate claims, data entry errors, forged prescriptions and intentional overcharging.

Pharmacy fraud, waste and abuse impacts everyone and results in misused benefits, safety issues and unnecessary financial losses. Pharmacy benefit managers (PBMs) can play a key role in safeguarding plan sponsors and their members by detecting and investigating potential fraud, waste and abuse. In turn, plan sponsors can protect their members from the risks of disrupted care and unnecessary costs by partnering with a PBM that has a holistic fraud, waste and abuse program in place or supplementing its existing program with services and tools from an additional PBM partner.

At Navitus, our robust fraud, waste and abuse program investigates the entire prescribing journey, from provider to pharmacy to member, while satisfying regulatory program standards for Medicare, Medicaid and other federal programs. Plan sponsors looking to enhance their existing fraud, waste and abuse program around pharmacy services can now partner with Navitus to discover potential outliers and supplement investigation resources. By combining our extensive experience with access to pharmacy data, provider prescribing patterns and member claims, we are uniquely positioned to offer plan sponsors support they need to prevent, detect and recover losses from fraud, waste and abuse.

Why does discovering fraud, waste and abuse matter?

Fraud occurs when someone knowingly uses false information or statements to improperly obtain payment for prescription drugs. Waste is when there is overutilization of services that results in unnecessary costs. Abuse includes actions that may result in unnecessary or increased payment for prescription drugs. In any of these circumstances, there may be opportunities to recover claims, provide education or apply controls to prevent financial loss, improve safety and support claims integrity.

Combatting fraud, waste and abuse

Whether a pharmacy sends drugs that were never ordered to a patient, a person falsely states drugs were lost or stolen and requests replacement drugs, or a pharmacy dispenses without a valid prescription, PBMs have a front row seat to uncover the issues. PBMs leverage innovative data analytic tools to identify suspicious patterns and investigate the underlying source, including:

Pre-payment Claim Review

Pharmacy Audits

Analysis of Industry, Program and Fraud Alerts

Pharmacy, Patient and Prescriber Investigations

To ensure vigilance and integrity within healthcare, we must remain committed to identifying and resolving fraudulent, abusive or wasteful behavior. By combatting these issues with experience, data and robust tools, PBMs can help plan sponsors improve healthcare performance and drive better financial results and member safety. Strong collaboration between the PBM and plan sponsor can yield the greatest opportunity to lower costs and effectively manage fraud, waste and abuse.

WRITTEN BY CARRIE AIKEN, CHC

Carrie serves as both the Vice President of Corporate Compliance and Navitus’ Compliance and Privacy Officer. She has more than 25 years of experience across multiple health care disciplines, including physician, hospital, home health and pharmacy, as well as contracting and revenue cycle management.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

Breaking Through Barriers with Value-Based Plan Design

Breaking Through Barriers with Value-Based Plan Design

Facing increased pharmacy benefit expenses, Blain’s Farm and Fleet, a Midwestern employer group, desired to improve plan performance. Specifically it was interested in educating eligible members about the benefits available to them, promoting cost-effective…

Finding a Solution to Lower Prescription Drug Costs

Finding a Solution to Lower Prescription Drug Costs

The Rural Arizona Group Health Trust (RAGHT) wanted to gain better control of its escalating drug trend with its large, traditional pharmacy benefit manager (PBM). Having only worked with traditional PBMs in the past, RAGHT was interested in exploring…

previous arrow
next arrow